Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ce Shi

Showing results (351-360 of 356) with videos related to

Pageof 36
Sort By:
You have reached the last page of results.This site can display upto 356 results.
Oncotarget|March 1, 2018
Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in <i>CRLF2</i> rearranged and/or <i>JAK</i> driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemiaQi Zhang, Ce Shi, Lina Han, et al.
Cell Transplantation|April 30, 2025
Comparison of plasma sterilizer and conventional laminar flow room in allogeneic hematopoietic stem cell transplant recipientsTing Wang, Yi Xia, Wei Hu, et al.
Haematologica|May 25, 2019
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia modelsLina Han, Qi Zhang, Monique Dail, et al.
Nature Communications|February 7, 2013
Genome of the Chinese tree shrewYu Fan, Zhi-Yong Huang, Chang-Chang Cao, et al.
Signal Transduction and Targeted Therapy|February 21, 2022
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Signal Transduction and Targeted Therapy|April 2, 2022
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Pageof 36

Showing results (351-360 of 356) with videos related to

Sort By:
Pageof 36
You have reached the last page of results.This site can display upto 356 results.
Oncotarget|March 1, 2018
Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in <i>CRLF2</i> rearranged and/or <i>JAK</i> driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemiaQi Zhang, Ce Shi, Lina Han, et al.
Cell Transplantation|April 30, 2025
Comparison of plasma sterilizer and conventional laminar flow room in allogeneic hematopoietic stem cell transplant recipientsTing Wang, Yi Xia, Wei Hu, et al.
Haematologica|May 25, 2019
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia modelsLina Han, Qi Zhang, Monique Dail, et al.
Nature Communications|February 7, 2013
Genome of the Chinese tree shrewYu Fan, Zhi-Yong Huang, Chang-Chang Cao, et al.
Signal Transduction and Targeted Therapy|February 21, 2022
Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Signal Transduction and Targeted Therapy|April 2, 2022
Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemiaQi Zhang, Bridget Riley-Gillis, Lina Han, et al.
Pageof 36